Cue Biopharma (CUE) analyst forecast and price target
Analyst forecast
Consensus of 2 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| LUCID CAPITAL MARKETS | Initiated Coverage | Buy | $4.00 | Aug 25, 2025 |
| Citizens Capital Markets | Maintained | Market Outperform | $2.00 | Apr 2, 2025 |
| Stifel | Maintained | Buy | $4.00 from $8.00 | Aug 20, 2024 |
| Piper Sandler | Maintained | Overweight | $3.00 from $8.00 | Jul 26, 2024 |
| JMP Securities | Maintained | Market Outperform | $2.00 from $15.00 | Jul 26, 2024 |
| Oppenheimer | Maintained | Outperform | $10.00 | Apr 9, 2024 |
| Stifel | Maintained | Buy | $8.00 | Apr 9, 2024 |
| Piper Sandler | Maintained | Overweight | $8.00 | Apr 3, 2024 |
| Jefferies | Initiated Coverage | Buy | $6.00 | Mar 13, 2024 |
| Piper Sandler | Maintained | Overweight | $8.00 from $7.00 | Nov 6, 2023 |
| Stifel | Maintained | Buy | $8.00 | Jun 15, 2023 |
| JMP Securities | Maintained | Outperform | $15.00 | May 15, 2023 |
Frequently asked questions
Is CUE a buy, sell, or hold?
Analysts covering Cue Biopharma currently average a Buy rating: 2 buy, 0 hold and 0 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on CUE?
On Aug 25, 2025, LUCID CAPITAL MARKETS initiated coverage of Cue Biopharma at Buy with a price target of $4.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.